Hospital
Cuyuna Regional Medical Center
Cuyuna Regional Medical Center was paid $7.05M by Medicaid between Jan 2018 and Dec 2024, across 80 billing codes. Its largest line is 99283, emergency room visit (moderate) — 35% of everything it billed.
33Billing provider infoCUYUNA REGIONAL MEDICAL CENTER
CROSBY, MN 56441
CROSBY, MN 56441
33aNPI1538143896assigned 12/01/2005
33bProvider typeCritical Access Hospital
28Total paid$7.05M
24GClaims63,376
24DCodes billed80
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Minnesota
Rank by total paid#5 of 68
Median peer was paid$798K
This provider vs. median8.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 11,399 | $458K | |
| 2019 | 10,999 | $1.17M | |
| 2020 | 7,517 | $750K | |
| 2021 | 7,696 | $864K | |
| 2022 | 9,457 | $1.32M | |
| 2023 | 10,052 | $1.52M | |
| 2024incomplete | 6,256 | $978K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 35% | 10,819 | 9,124 | $2.47M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 31% | 12,089 | 9,981 | $2.18M |
| A0426 | Ambulance service, advanced life support, non-emergency transport, level 1 (als 1) | 7.7% | 1,263 | 1,067 | $543K |
| A0425 | Ground mileage, per statute mile | 6.3% | 1,782 | 1,491 | $443K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.2% | 2,217 | 1,927 | $367K |
| A0427 | Emergency ambulance ride, advanced life supportAmbulance service, advanced life support, emergency transport, level 1 (als 1 - emergency) | 2.3% | 316 | 263 | $159K |
| 36415 | Collection of venous blood by venipuncture | 1.7% | 7,889 | 6,876 | $122K |
| X5622 | 1.6% | 616 | 507 | $112K | |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 1.5% | 2,120 | 1,866 | $103K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.2% | 787 | 703 | $81K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 1.0% | 2,381 | 2,138 | $72K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 3,963 | 3,206 | $64K |
68 more codes
| 80306 | <1% | 3,313 | $47K | |
| 80053 | Comprehensive metabolic panel | <1% | 1,236 | $47K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 705 | $45K |
| 97803 | <1% | 652 | $28K | |
| 73630 | <1% | 115 | $21K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 1,174 | $14K |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 1,211 | $14K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 348 | $11K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 87 | $10K |
| 72100 | <1% | 43 | $9K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,891 | $9K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 158 | $7K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 134 | $4K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 64 | $4K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 16 | $4K |
| J3490 | Unclassified drugs | <1% | 923 | $4K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 52 | $3K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 118 | $3K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 160 | $3K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 82 | $3K |
| 73110 | <1% | 17 | $3K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 114 | $3K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 94 | $3K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 37 | $2K |
| 87210 | <1% | 123 | $2K | |
| 87400 | <1% | 127 | $2K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 86 | $2K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 172 | $2K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 31 | $2K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 54 | $2K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 736 | $1K |
| 80061 | Lipid panel | <1% | 41 | $1K |
| 86900 | <1% | 16 | $1K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 43 | $1K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 30 | $1K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 520 | $1K |
| 36591 | <1% | 29 | $1K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 55 | $1K |
| 82728 | <1% | 13 | $947.41 | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 716 | $890.85 |
| 86850 | <1% | 16 | $824.41 | |
| 83615 | <1% | 53 | $795.00 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 37 | $684.24 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 190 | $659.48 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 69 | $652.78 |
| 81001 | <1% | 44 | $601.85 | |
| 86901 | <1% | 16 | $582.70 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 41 | $565.04 |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 13 | $527.76 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 16 | $496.05 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 23 | $494.63 |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | <1% | 34 | $478.48 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 12 | $417.13 |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 132 | $375.59 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 113 | $365.24 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 59 | $189.20 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 71 | $162.57 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 13 | $115.85 |
| 0004A | <1% | 13 | $82.08 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 21 | $46.65 |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 13 | $27.07 |
| 92551 | <1% | 53 | $23.80 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 14 | $20.16 |
| 99173 | <1% | 52 | $3.19 | |
| S0302 | Completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service) | 0% | 416 | $0.00 |
| 83605 | 0% | 15 | $0.00 | |
| 91300 | 0% | 36 | $0.00 | |
| 99238 | Hospital discharge day management, 30 minutes or less | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBERG, KATIE (CFO)
| Provider | Location | Paid |
|---|---|---|
| Cuyuna Regional Medical Center | Crosby, MN | $3.75M |
| Cuyuna Regional Medical Center | Longville, MN | $1.44M |
| Sleep Center of Central Minnesota LLC | Baxter, MN | $351K |
| Sleep Center of Central Minnesota, LLC | Baxter, MN | $4K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.